Evans John M. 4

What Happened John M. Evans, CEO and director of Beam Therapeutics (BEAM), exercised stock options and sold shares in late March 2026. He exercised 25,000 options on 2026-03-30 and another 25,000 on 2026-03-31 at a $0.67 exercise price (total exercise cost $33,500). He sold 25,000 shares on 2026-03-30 at a weighted-average price of $22.37 (proceeds $559,230) and 25,000 shares on 2026-03-31 at a weighted-average price of $22.76 (proceeds $569,085), for total sale proceeds of approximately $1,128,315. On 2026-03-31 he also received a grant of 90,000 restricted stock units (RSUs) (no cash value at grant).

Key Details

• Transaction dates: 2026-03-30 and 2026-03-31; filing date: 2026-04-01 (period of report 2026-03-30). No late filing indicated in the provided excerpt.
• Sales: 25,000 shares on 3/30 at a weighted avg $22.37 (range $22.03–$22.70 per F2); 25,000 shares on 3/31 at a weighted avg $22.76 (range $22.34–$23.21 per F3).
• Option exercises: 25,000 shares exercised on 3/30 and 25,000 on 3/31 at $0.67 per share (total exercise cost $33,500).
• Award: 90,000 RSUs granted on 3/31 (F4); RSUs vest in four roughly equal annual installments, subject to continued service.
• Sales were made pursuant to a Rule 10b5-1 trading plan adopted May 16, 2025 (F1).
• Shares owned after the transactions are not specified in the provided filing excerpt.
• Footnote F5 references an earlier 2018 option grant and a performance-based vesting that occurred in 2024; not directly altering these March 2026 transactions.

Context

• This filing shows option exercises followed by open-market sales under a pre-established 10b5-1 plan, a common practice for executives to monetize vested equity while avoiding concerns about trading on inside information. The combination of exercise + sale is effectively an exercise-and-sell sequence (proceeds far exceed exercise cost).
• The 90,000 RSU grant is a time-vesting award and does not represent immediate transferable shares; it vests over four years if service conditions are met.
• As always, filings are factual disclosures and do not by themselves indicate the insider’s view of the company’s prospects.